AI Drug R&D Startup XtalPi Announces Over 300 Million Series C Investment Led by SoftBank Vision Fund, PICC Capital, and Morningside
With the new round of funding, XtalPi will bring the power of quantum physics, AI, and almost limitless cloud resources to propel research scientists towards drug candidates with tailored pharmaceutical profiles. Its platform takes the unique approach of combining physics-based and data-driven models to comprehensively address all drug properties relevant to progression into clinical studies. By integrating the predictions of its virtual R&D platform with real-world data from modern laboratories, XtalPi will develop a digital-twin drug R&D system to provide a scalable and sustainable advantage that translates to more promising drug candidates with fewer experiments in less time.
"In the past few years, we have focused on developing and validating our platform's capabilities by working with some of the top innovative pharmaceutical and biotech companies in the world," said Dr.
"We believe AI holds the answer to solving pharma's productivity challenge. More specifically, XtalPi's AI-powered platform can improve the industry's research efficiency and success rate in order to lower costs for discovering and developing new drugs. We look forward to applying our platform to help clients bring more first-in-class and breakthrough drugs to the market and address significant unmet medical needs to benefit patients on a global scale."
In the next steps, XtalPi will expand its Intelligent Digital Drug Discovery and Development (ID4) platform's capabilities through a three-pronged approach focused on algorithms, data, and computing power to address efficiency bottlenecks throughout the critical steps of pharmaceutical research.
With quantum-based theories and AI models at its core, XtalPi's platform hosts over a hundred prediction algorithms. It can accurately describe the interaction between molecules and proteins at the atomic level, and map various feature vectors of a compound to key pharmacology properties. The company also leverages the massive amount of high-accuracy data in the chemical space of drug-like molecules generated from quantum mechanics calculations for data analysis and model training. XtalPi maintains a petabyte-scale database consisting of pharmaceutically active molecules and key drug characteristics that continues to grow as its business rapidly expands.
Across several prominent global cloud providers, XtalPi routinely builds a supercomputing cluster of over a million cores on-the-fly, in just a few hours, to enable dozens of drug discovery and design projects in parallel. In developing its digital-twin drug R&D system, XtalPi will continue to match real-world R&D data with increasingly powerful virtual simulations at scale and extend its existing success to serve a larger number of biotech partners, therapeutic areas, and drug discovery projects.
"We believe XtalPi is a leader in transforming drug discovery through its innovative multi-disciplinary approach," said
"Morningside has long emphasized the intersection of computer science and life science in our investment. In the AI-driven efficiency revolution, XtalPi's platform offers a robust new foundation for pharmaceutical innovations. We look forward to a new era of human health brought by the seamless integration of state-of-the-art information technologies and biotechnology."
Media Contact:
About XtalPi
XtalPi is a pharmaceutical technology company that is reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi's ID4 platform provides accurate predictions on the physicochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide.
Founded in 2014 by a group of quantum physicists at
About
About
About Morningside
i As of the date of this press release, SoftBank Group Corp. has made capital contributions to allow investments by
View original content to download multimedia:http://www.prnewswire.com/news-releases/ai-drug-rd-startup-xtalpi-announces-over-300-million-series-c-investment-led-by-softbank-vision-fund-picc-capital-and-morningside-301139002.html
SOURCE
American Equity, Varde Partners And Agam Capital Management To Partner
The only debate moderator to return, Fox's Wallace preps
Advisor News
- SEC: Get-rich-quick influencer Tai Lopez was running a Ponzi scam
- Companies take greater interest in employee financial wellness
- Tax refund won’t do what fed says it will
- Amazon Go validates a warning to advisors
- Principal builds momentum for 2026 after a strong Q4
More Advisor NewsAnnuity News
- How next-gen pricing tech can help insurers offer better annuity products
- Continental General Acquires Block of Life Insurance, Annuity and Health Policies from State Guaranty Associations
- Lincoln reports strong life/annuity sales, executes with ‘discipline and focus’
- LIMRA launches the Lifetime Income Initiative
- 2025 annuity sales creep closer to $500 billion, LIMRA reports
More Annuity NewsHealth/Employee Benefits News
- Lawmakers advance Reynolds’ proposal for submitting state-based health insurance waiver
- Proposal would help small businesses afford health insurance
- Lamont proposes 'Connecticut Option' to help small businesses afford health insurance
- Colorado lawmakers target 'ghost networks' to expand access to mental health care
- NCD WELCOMES COUNCILMEMBER BRIAN PATCHETT
More Health/Employee Benefits NewsLife Insurance News